VANCOUVER, June 1 /CNW/ - CRH Medical Corporation (CRM:TSX-V, CRMMF: OTCQX) announced today that Dr. David Johnson has been elected to its board of directors.
Dr. Johnson is a past President of American College of Gastroenterology and a partner of Gastrointestinal and Liver Specialists of Tidewater PLLC in Norfolk, VA. Dr. Johnson has authored more than 500 papers in the field of gastroenterology and serves as Professor of Medicine, Chief of Gastroenterology, Eastern Virginia Medical School.
"We are very excited about Dr. Johnson's appointment to our Board of Directors. Dr. Johnson's in depth knowledge of the gastroenterology community and his experience as a clinician and educator will significantly enhance our efforts to maximize the introduction and adoption of the CRH O'Regan System." stated Chief Executive Officer Edward Wright.
Commenting on his appointment, Dr. Johnson said, "As an early adopter of the CRH O'Regan System, it is a privilege to serve as a member of the CRH Board of Directors. I will work with CRH to increase the awareness of the CRH O'Regan as it represents a significant opportunity for all gastroenterologists to improve their practice as well as the care they provide their patients."
In conjunction with Dr. Johnson's appointment to its Board of Directors the Company has issued Dr. Johnson an option to purchase up to 100,000 common shares in the Company exercisable at a price of CDN$1.45 for a period of 5 years pursuant to its Stock Option Plan.
About CRH Medical Corporation:
CRH Medical Corporation specializes in the treatment of hemorrhoids utilizing its proven treatment protocol and patented proprietary technology. CRH's single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I - IV. CRH Medical employs two commercialization strategies: First, it operates Centers for Colorectal Health facilities in the United States specializing in the treatment of hemorrhoids and fissures, and colon cancer screening. In addition CRH distributes its hemorrhoid banding technology, treatment protocols, operational and marketing expertise as a complete, "turn key" package directly to its partner physicians. The Company's goal is to establish the CRH hemorrhoid technology as the standard for hemorrhoid treatment.
For further information call Dean Linden, Corporate Communications, CRH Medical Corporation at 604.633.1440 or firstname.lastname@example.org. Additional information may also be found by visiting the Company's website at www.crhmedcorp.com or the SEDAR website at www.sedar.com.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE CRH Medical Corporation
For further information: For further information: Investor Contact: Dean Linden, (604) 633-1440